The Board of Directors of Moberg Pharma has resolved on record date for the reverse share split

The Board of Directors of Moberg Pharma has resolved on record date for the reverse share split

The Annual General Meeting in Moberg Pharma AB (publ) (“Moberg Pharma” or the “Company”) on 16 May 2023 resolved on a reverse share split, through which ten existing shares will be consolidated into one share (Sw: Sammanläggning 1:10). The Board of Directors was authorized by the Annual General Meeting to resolve on the record date for the reverse share split. The Board of Directors now resolved that the record date for the reverse share split will be 25 May 2023.

The Board of Directors' resolution means that the last day of trading in Moberg Pharma's share prior to the reverse share split will be 23 May 2023 and the first day of trading in the share after the reverse share split will be 24 May 2023 This means that the share price as from and including 24 May 2023 will reflect the effect of the reverse share split. As a result of the reverse share split, the shares in Moberg Pharma will as from and including 24 May 2023 have a new ISIN-code SE0020353928.

Following the reverse share split, the number of shares in the Company will decrease from 100,859,335 to 10,085,933. The proposed reverse share split will result in a change of the share’s quotient value from SEK 0.1 to approximately SEK 1.

For additional information, please contact:
Anna Ljung, CEO, telephone: +46 70 766 60 30, e-mail: anna.ljung@mobergpharma.se
Mark Beveridge, Vice President Finance, telephone: +46 76 805 82 88, e-mail: mark.beveridge@moberpharma.se

About this information
The information was submitted for publication at 10.00 a.m. on 17 May 2023 through the contact persons above.

About Moberg Pharma, www.mobergpharma.com
Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The Company’s main asset, MOB-015, is a novel topical treatment for onychomycosis. Data from phase 3 clinical trials in more than 800 patients for MOB-015 indicate that the product has the potential to become the future market leader in onychomycosis. Moberg Pharma has agreements with commercial partners in place in Europe and Canada, among others, and the Company's goal is to receive its first market approval in 2023. Moberg Pharma is headquartered in Stockholm and the Company’s shares are listed on the Small Cap list of the Nasdaq Stockholm (OMX: MOB).